Kevin Lobo joins GE HealthCare (Nasdaq: GEHC) board

Rhea-AI Filing Summary

GE HealthCare Technologies Inc. reported that its Board appointed Kevin A. Lobo, Chair and CEO of Stryker Corporation, as a director effective March 13, 2026, and named him to the Talent, Culture, and Compensation Committee. His term runs until the 2026 Annual Meeting and he will be compensated under the company’s standard non-employee director program, with an indemnification agreement matching the form used for other directors.

The company also disclosed that directors Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting due to other commitments, and their decisions do not reflect any disagreement with the company. A press release announcing Mr. Lobo’s appointment was issued on March 17, 2026 and furnished as an exhibit.

0001932393false00019323932026-03-132026-03-13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 13, 2026

GE HEALTHCARE TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41528

88-2515116

(State or other jurisdiction of incorporation)

(Commission  File Number)

(IRS Employer Identification No.)

500 W. Monroe Street,

Chicago,

IL

60661

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code) (833) 735-1139

______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.01 per share

GEHC

The Nasdaq Stock Market LLC

			Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
			Emerging growth company			☐
			If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.			☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Kevin A. Lobo to serve as a director of the Company, effective immediately. Mr. Lobo’s term will expire at the Company’s 2026 Annual Meeting of Stockholders. The Board also appointed Mr. Lobo as a member of the Talent, Culture, and Compensation Committee of the Board, effective immediately.

Mr. Lobo will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025. The Company will also enter into an indemnification agreement with Mr. Lobo. The form of indemnification agreement is included as Exhibit 10.3 to the Company’s Annual Report on Form 10-K filed with the SEC on February 4, 2026.

There is no arrangement or understanding between Mr. Lobo and any other person pursuant to which he was selected as a director. There are no transactions between Mr. Lobo and the Company that would be reportable under Item 404(a) of Regulation S-K.

Also on March 13, 2026, each of Risa Lavizzo-Mourey and Tomislav Mihaljevic informed the Board that they would not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders due to other commitments. Neither Dr. Lavizzo-Mourey’s nor Dr. Mihaljevic’s decision was a result of any disagreement on a matter related to the Company’s operations, policies, or practices.

Item 7.01 Regulation FD Disclosure.

On March 17, 2026, the Company issued a press release announcing the appointment of Kevin A. Lobo to its Board. A copy of the press release is furnished as Exhibit 99.

The information furnished pursuant to Item 7.01, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit			Description
99			Press Release of GE HealthCare Technologies Inc., dated March 17, 2026.
104			The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GE HealthCare Technologies Inc.
						(Registrant)
Date: March 17, 2026						/s/ Frank R. Jimenez
						Frank R. Jimenez, General Counsel and Corporate Secretary (authorized signatory)

GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

CHICAGO —(BUSINESS WIRE)— March 17, 2026— GE HealthCare (Nasdaq: GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE: SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare’s strategic priorities.

“Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and sustainable future for healthcare,” said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. “We look forward to benefiting from his perspective as we execute on our growth and innovation priorities.”

Mr. Lobo has served as the Chief Executive Officer of Stryker Corporation since October 2012 and as chair of the Stryker Board of Directors since July 2014. Prior to this, he held leadership positions in Stryker’s Orthopedics Group and Neurotechnology and Spine Group. Mr. Lobo’s depth of experience includes operations leadership at Johnson & Johnson, including as President of Ethicon Endo Strategy, and Rhône-Poulenc, a chemical and pharmaceutical company. Earlier in his career, he held finance roles of increasing responsibility at KPMG, Unilever and Kraft Canada.

"GE HealthCare plays a critical role in shaping the future of healthcare through advanced technology, novel pharmaceutical diagnostics, and global reach," said Kevin Lobo. "I look forward to serving on its Board and working with the management team as it executes on its strategy to enable more precise patient care, drive growth, and create long-term value."

Media Contact:

Jennifer Fox

Head of External Corporate Communications

+1 414 530 3027

jennifer.r.fox@gehealthcare.com

Investor Relations Contact:

Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care

Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives. 

FAQ

What board changes did GEHC report in this 8-K filing?

GE HealthCare reported that Kevin A. Lobo was appointed to its Board of Directors and Talent, Culture, and Compensation Committee, effective March 13, 2026. The filing also noted that directors Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting.

Who is Kevin A. Lobo and what is his role at GE HealthCare (GEHC)?

Kevin A. Lobo is Chair and Chief Executive Officer of Stryker Corporation. He has been appointed to GE HealthCare’s Board of Directors and its Talent, Culture, and Compensation Committee, bringing more than 25 years of medical technology, operational, and financial leadership experience to the company.

Why are Risa Lavizzo-Mourey and Tomislav Mihaljevic leaving the GEHC board?

Risa Lavizzo-Mourey and Tomislav Mihaljevic informed GE HealthCare’s Board that they will not stand for re-election at the 2026 Annual Meeting because of other commitments. The company stated that their decisions were not due to any disagreement over operations, policies, or practices.

How will Kevin Lobo be compensated as a GEHC director?

Kevin Lobo will receive compensation under GE HealthCare’s existing program for non-employee directors. The company referenced its Definitive Proxy Statement filed April 10, 2025, and indicated it will enter into an indemnification agreement with him in the form used for other directors.

What does the press release attached to GEHC’s 8-K highlight?

The press release highlights Kevin Lobo’s appointment to GE HealthCare’s Board effective March 13, 2026, emphasizing his extensive medtech, operational, and financial background. It includes supportive statements from Chairman H. Lawrence Culp, Jr. and from Mr. Lobo about contributing to GE HealthCare’s growth and innovation priorities.

How large is GE HealthCare Technologies Inc. as described in the filing content?

GE HealthCare describes itself as a $20.6 billion business with approximately 54,000 colleagues worldwide. The company positions itself as a leading global provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions for more personalized and precise patient care.

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99 EX-99 10.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB